Bridges, Sarah
Fowler, Samantha
McLaughlin, Lauren
Robichaud, Marc
Ridgway, Barbara
Reece, Donna
Song, Kevin
Dalrymple, Lorelei
Sully, Robin
Nason, Sharon
Rowland, Suzanne
MacDonald, Trish
Paine, William
Gulliver, Adrienne
Reiman, Anthony
Funding for this research was provided by:
Canadian Institutes of Health Research
New Brunswick Health Research Foundation
Myeloma Canada
Canadian Cancer Society
Terry Fox Research Institute
Article History
Received: 14 April 2023
Accepted: 20 July 2023
First Online: 29 July 2023
Declarations
:
: All phases of this study were reviewed and approved by the Horizon Health Network Human Research Protection Program including the Research Ethics Board. Informed consent was obtained from participants before each survey and the consensus-building workshop.
: Not applicable.
: DR reports consultancy for and honoraria and research funding from Janssen, Celgene, a Bristol-Myers Squibb company, Amgen, Takeda, serving on board of directors or advisory committee for Janssen and Celgene, a Bristol-Myers Squibb company, honoraria and research funding from Merck and research funding from Otsuka; TR reports contracts with AstraZeneca, Roche, Pfizer, Amgen and BristolMyersSquibb; KS reports honoraria and research funding from Celgene, a Bristol-Myers Squibb company, Janssen, Amgen, Takeda; LD, DR, TR and WP are members of the Myeloma Canada Board of Directors.